Exploring Biomarkers in Age Stratified PUMCH Dementia Cohort

NCT04924361 | Unknown

• 1 other identifier: PUMCH Dementia Cohort Research
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

Biomarkers are important for early and precise diagnosis of dementia. However, the causes of dementia in different age are different. We designed an age stratified dementia cohort and tried to explore biomarkers of different groups of dementia, incorporating neuropsychology, multi-model neuroimaging, metabolics and proteomics based fluid biomarkers as well as genetic biomarkers. Autopsy after clinical follow up help to verify the biomarkers.

Conditions

Dementia; Dementia, Vascular; Dementia Frontal; Dementia, Mixed; Dementia Alzheimers; Dementia With Lewy Bodies

Keywords

Biomarkers; Diagnosis

Outcome Measures

Primary Outcomes (1)

• Incorporating age stratified biomarkers into the diagnosis of dementia

  Comparing the relationships between biomarkers and clinical presentations as well as neuroimaging. Incorporate biomarkers into the accurate and early diagnosis of dementia

  Through study completion,an average of 5 years

Secondary Outcomes (2)

• Establishing dementia cohort including detailed clinical information, fluid samples and brain bank

  Through study completion,an average of 5 years

• Exploring 5-10 kinds of age stratified biomarkers, including neuropsychology, neuroimaging, fluid biomarkers and genetic biomarkers

  Through study completion,an average of 5 years

Study Arms (4)

Early onset dementia

Dementia patients with onset age lower than 65y/o

Late onset dementia

Dementia patients with onset age between 65y/o and 85y/o

Oldest old dementia

Dementia patients with onset age older than 85y/o

Cognitive normal control

cognitive normal control

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

We included age stratified dementia (early onset, late onset, oldest old) , including AD, FTD,VaD, DLB and mixed dementia. Also we include cognitive normal controls.

You may qualify if:

• Neurodegenerative dementia diagnosis based on 2011 NIA-AA criteria of Dementia
• Fixed care giver and can follow up regularly

You may not qualify if:

• Not demented, including MCI
• Systemic severe diseases and severe vision or hearing problem effecting follow up and neuropsychological evaluation
• Without fixed care giver
• Reject informed consent
• Expected life shorter than 2 years

Sponsors & Collaborators

• Peking Union Medical College Hospital: lead

Study Sites (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

RECRUITING

Related Publications (4)

• Kuruppu DK, Matthews BR. Young-onset dementia. Semin Neurol. 2013 Sep;33(4):365-85. doi: 10.1055/s-0033-1359320. Epub 2013 Nov 14.

  PMID: 24234358 BACKGROUND

• Rabinovici GD. Late-onset Alzheimer Disease. Continuum (Minneap Minn). 2019 Feb;25(1):14-33. doi: 10.1212/CON.0000000000000700.

  PMID: 30707185 BACKGROUND

• Yang Z, Slavin MJ, Sachdev PS. Dementia in the oldest old. Nat Rev Neurol. 2013 Jul;9(7):382-93. doi: 10.1038/nrneurol.2013.105. Epub 2013 Jun 4.

  PMID: 23732531 BACKGROUND

• Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018.

  PMID: 29653606 BACKGROUND

MeSH Terms

Conditions

Dementia; Dementia, Vascular; Mixed Dementias; Alzheimer Disease; Lewy Body Disease; Disease

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Mental Disorders; Cerebrovascular Disorders; Intracranial Arteriosclerosis; Intracranial Arterial Diseases; Leukoencephalopathies; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases; Tauopathies; Neurodegenerative Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Jing Gao, Doctor

  Peking Union Medical College Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Chenhui Mao, Doctor

CONTACT

+86018611895308; maochenhui@pumch.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor, Department of Neurology

Study Record Dates

• First Submitted: May 18, 2021
• First Posted: June 14, 2021
• Study Start: December 1, 2020
• Primary Completion: November 1, 2025
• Study Completion: November 1, 2025
• Last Updated: September 13, 2022

Record last verified: 2022-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)